Replies to post #8127 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>After the EMEA debacle the future of Atryn and even GTCB's platform was teetering on the abiss. If they had not gotten a reversal who knows what might of happened and they close to being out of money then. I talked to Cox at the shareholder after the negative opinion,,,,it was a really dark time..I got the sense then of his determination that he was a good CEO for the company.<

Dr. Cox was the right CEO when GTC’s overriding goal was to have the first transgenically-produced drug approved anywhere in the world. Well done.

Now, however, the skill set needed at the top to build a successful business is rather different from what was needed in 2006.

[OKY]

jessellivermore

I appreciate your support. I see you have similar ideas. Yes
we don't know a thing. WE pretend we are in the boardroom.

It’s comical really. Someone will make a supposition, which
is really a projection of there own personality, then
they say it out loud where they need to defend it.

In defending it they make it the truth. If someone disagrees,
it becomes a personal attack and all kinds of suppositions
come in to defend what never could be defended.

After a while, if a person sticks with their story or ideas
long enough, it becomes Gospel helping to forms their
persona.

Gees, just think, we all do that. Holy cow what is real
and what isn't? We have no clue do we.

[poorgradstudent]

>My point is.....we just do not know the circumstances and answers to many {most) of the issues raised on this board.<

With all due respect, this is not a constructive mindset. It is typical for retail to rationalize events by saying "we don't know *exactly* what happened."

That's just a way to signal that things didn't go as you / we were led to believe, and other than conclude that management failed to provide what they telegraphed to investors, you conclude that there are too many moving parts and therefore we can't judge.

We do know, for a certainty, that the company was just diluted 10% or so. That's a fact, and not a positive one. Therefore, the "unknowns" that led to this dilution could not have been positive ones either; in other words, management failed at some point.

If investors don't concede that simple fact, then more trouble lies ahead.